Abstract Library

#4226 Pancreatic neuroendocrine tumors – Epidemiological profile and surgical aspects

Introduction: Pancreatic neuroendocrine tumors (NET) are rare tumors, with an incidence of less than 0.5 cases per 100,000 people, PTNE represents 5% of pancreatic tumors, surgical treatment has a central place because it is the only treatment potentially curative if the resection is complete.

Conference:

Presenting Author:

Authors: Bennaoum S, Kaid M,

Keywords: pancreatic neuroendocine tumor surgery,

#4078 Prostate-specific membrane antigen-targeting theranostics in neuroendocrine neoplasms – Initial results from the GI-PSMA phase II trial

Introduction: A single-center Phase II trial (“GI-PSMA”, NCT05547919) was conducted to evaluate prostate-specific membrane antigen (PSMA)-targeted theranostics in gastroenteropancreatic tumors.

Conference:

Presenting Author: Weich A

Authors: Weich A, Serfling S, Bayer J, Buck A, Bley T,

Keywords: neuroendocrine, PSMA-PET/CT, dosimetry, high-grade NEN, PSMA,

#3892 Precision medicine in pancreatic MiNEN and other rare pancreatic histologies – A case series from Verona University Hospital

Introduction: Rare tumors of the pancreas represent orphan neoplasms. Better knowledge of their biology will allow more effective treatments to be offered to affected patients.

Conference:

Presenting Author: Trevisani E

Authors: Trevisani E, Mafficini A, Benini L, Borghesani M, Rossi A,

Keywords: Precision medicine, rare pancreas, NGS, gene mutation, MiNEN,

#3877 Short fasting test as a reliable and effective tool to diagnose insulinoma

Introduction: Insulinomas are pancreatic NETs presenting with hypoglycaemia. Current guidelines for its diagnosis require a prolonged fasting test (72 hours), which implies hospitalization and is difficult to perform. It has been reported that up to 85% of insulinomas are diagnosed within a 24h fasting period.

Conference:

Presenting Author: Mikovic N

Authors: Mikovic N, Mazzilli R, Zamponi V, Russo F, Faggiano A,

Keywords: insulinoma, neuroendocrine pancreatic tumor, functioning NET, hypoglycaemia,

#3789 Comparison of postoperative textbook outcome between pancreatic neuroendocrine tumor and pancreatic ductal adenocarcinoma – A nationwide retrospective cohort study

Introduction: Pancreatic neuroendocrine tumors (pNET) represent only 6% of pancreatic tumors, compared to 93% for pancreatic ductal adenocarcinoma (PDAC). Textbook outcome (TO) is a composite outcome measure that reflects a hospital’s surgical performance as well as quality of current practice.

Conference:

Presenting Author: Chen J

Authors: Chen J, Augustinus S, Engelsman A, Bonsing B, Groot Koerkamp B,

Keywords: pNET, PDAC, Dutch Pancreatic Cancer Audit, Textbook Outcome, Postoperative results,